Richmond University   Report issue

Academic/Hospital Phase 1 Phase 4
Founded: London United Kingdom (1972)

Organization Overview

First Clinical Trial
2007
NCT00457405
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

RUNMC Department of Medical Oncology | RUNMC Department of Nuclear Medicine

Active Ingredients

Drugs in Phase 4 Trials (3)

caffeine (1 trial)

dipyridamole (persantine) (2 trials)

rosuvastatin (crestor) (1 trial)

Drugs in Phase 1 Trials (1)

imp288 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Colorectal Neoplasms (Phase 1)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Heart Diseases (Phase 4)

Ischemia (Phase 4)

Myocardial Ischemia (Phase 4)

Reperfusion Injury (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4